Pancreatic Cancer Research

ResearcherHenry Ford HealthActive in the last 2 years

David Kwon

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-2673-3758; OpenAlex author ID A5015987197. Sources: OpenAlex.

Their work

Papers
8 (first author 1, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
29
Papers, trials and grants by year

2014: 1 paper · 2015: 1 paper · 2016: none · 2017: none · 2018: none · 2019: none · 2020: 1 paper · 2021: 1 paper · 2022: none · 2023: none · 2024: 2 papers · 2025: 1 paper · 2026: 1 paper

Papers 8

  1. Spatial Transcriptomics on a Diverse Pancreatic Cancer Cohort Reveals Race-Related Differences in Tumor Subtypes and Immune Microenvironments. Co-author DOI 10.1158/0008-5472.can-25-2748↗
  2. Human Pancreatic Cancer Single-Cell Atlas Reveals Association of CXCL10+ Fibroblasts and Basal Subtype Tumor Cells. Co-author DOI 10.1158/1078-0432.ccr-24-2183↗
  3. Weakly supervised large-scale pancreatic cancer detection using multi-instance learning. Co-author DOI 10.3389/fonc.2024.1362850↗
  4. Long-Term Follow-Up of Phase I Trial of Oncolytic Adenovirus-Mediated Cytotoxic and Interleukin-12 Gene Therapy for Treatment of Metastatic Pancreatic Cancer. Co-author DOI 10.3390/biomedicines12051065↗
  5. Phase I trial of oncolytic adenovirus-mediated cytotoxic and interleukin-12 gene therapy for the treatment of metastatic pancreatic cancer. Last author DOI 10.1016/j.omto.2020.11.006↗
  6. Neoadjuvant Phase II Trial of Chemoradiotherapy in Patients With Resectable and Borderline Resectable Pancreatic Cancer. Co-author DOI 10.1097/coc.0000000000000688↗
  7. Treatment of 200 locally advanced (stage III) pancreatic adenocarcinoma patients with irreversible electroporation: safety and efficacy. First author DOI 10.1097/sla.0000000000001441↗
  8. Borderline and locally advanced pancreatic adenocarcinoma margin accentuation with intraoperative irreversible electroporation. Co-author DOI 10.1016/j.surg.2014.06.058↗

Closest collaborators

The 25 strongest of 29 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Gazala Naaz Khan · 3 shared papers, 2020–2024 · strength 0.49
  2. Nina G. Steele · 2 shared papers, 2025–2026 · strength 0.38
  3. Daniel James Salas-Escabillas · 2 shared papers, 2025–2026 · strength 0.38
  4. Debora Barbosa Vendramini Costa · 2 shared papers, 2025–2026 · strength 0.38
  5. Ling Huang · 2 shared papers, 2025–2026 · strength 0.38
  6. Ralph A. Francescone III · 2 shared papers, 2025–2026 · strength 0.38
  7. Ian M. Loveless · 2 shared papers, 2025–2026 · strength 0.38
  8. Yuesong Wu · 2 shared papers, 2025–2026 · strength 0.38
  9. Kailee M. Hartway · 2 shared papers, 2025–2026 · strength 0.38
  10. Howard C. Crawford · 2 shared papers, 2025–2026 · strength 0.38
  11. Shyam Nyati · 1 shared paper, 2024 · strength 0.26
  12. Aseem Rai Bhatnagar · 1 shared paper, 2024 · strength 0.26
  13. Shyamapada Mandal · 1 shared paper, 2024 · strength 0.24
  14. Anurag Singh Rathore · 1 shared paper, 2024 · strength 0.24
  15. Bin Chen · 1 shared paper, 2026 · strength 0.21
  16. Samantha B. Kemp · 1 shared paper, 2025 · strength 0.17
  17. Jacob T. Mitchell · 1 shared paper, 2025 · strength 0.17
  18. Elana Judith Fertig · 1 shared paper, 2025 · strength 0.17
  19. Luciane Tsukamoto Kagohara · 1 shared paper, 2025 · strength 0.17
  20. Ben Z. Stanger · 1 shared paper, 2025 · strength 0.17
  21. Andrew M. Waters · 1 shared paper, 2025 · strength 0.17
  22. Kenneth N. Barton · 1 shared paper, 2021 · strength 0.12
  23. Munther Ajlouni · 1 shared paper, 2021 · strength 0.12
  24. Robert C.G. Martin · 2 shared papers, 2014–2015 · strength 0.11
  25. Kannan Thanikachalam · 1 shared paper, 2020 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.